Jun 25 2009
GIA announces the release of a comprehensive global report on Nanomedicine markets. The global Nanomedicine market continues to register robust growth largely fueled by unique properties of nanoparticles that provide novel and improved advantages, introduction of novel products, healthy rise in funding across the globe, and increased hype around nanotechnology.
Nanomedicine represents a principal domain of nanotechnology that offers capability to significantly change the course of treatment of life-threatening diseases. Unlike other therapies, nanomedicine enhances efficacy and significantly minimizes adversities associated with standard therapeutics. The application of nanotechnology in the form of nanomedicine in areas including nano drug delivery, nanoanalytical contrast reagents, nanobiomaterials, and nanopharmaceuticals has been surging at a stable rate. Recent years saw implementation of several programs by the industry to bridge the gap between outcomes of clinical research and commercial products. As a result, the present nanobiomaterial product pipeline poses a healthy picture with numerous novel products for use in health care applications, primarily in the form of coatings. Further, research and development in the nanomedicine market is expected to offer several novel products that can effectively improve the health of patients suffering from health disorders and illnesses.
Drug delivery market represents the largest application area, while the Biomaterials segment represents the fastest growing application segment for nanomedicine over the years 2006 through 2015.
The nanomedicine market is highly fragmented and is characterized by the presence of several key and niche players. Major market participants in the nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies Inc., Starpharma Holdings Limited, and Wyeth Pharmaceuticals Inc., among others.
The report titled "Nanomedicine: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., covers major market dynamics, trends, issues, and competition pertaining to the market. Analytical estimates and projections on market size have been presented in terms of dollar sales over the time period 2006-2015. The report enumerates recent developments, mergers, acquisitions and other strategic industry activities. The study analyzes the nanomedicine market by the following application areas - Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials and Other Applications.